Competition with a shortlist
Competitive procedure with a selection stage: suppliers were shortlisted before being invited to bid.
Key facts
- Buyer
- East Sussex Healthcare NHS Trust · Body governed by public law
- Supplier
- Exact Sciences UK, Ltd. SME
- Value
- £272,700
- Procedure
- Call-off from a framework agreement
- Sector
- Health & social care · Pathology services (CPV 85111800)
- Region
- South East
- Official notice
- View on Contracts Finder
- Timeline
-
- Contract date2 Mar 2026
- Published3 Mar 2026Published 1 day after the contract date
Description
Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy decisions in specific cohorts of early breast cancer. It provides a Recurrence Score that stratifies patients into groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient. Additional information: This is a call off contract from framework 2023/S 000-028831 based on previous contracts usage.
About the supplier
Exact Sciences UK, Ltd.: every public contract they have won, plus their Companies House record (company 07484560).